Andrew E Aplin

Years Active: 2019-2019
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Jessica Gonçalves, Michael F Emmons, Fernanda Faião-Flores, Andrew E Aplin, J William Harbour, Jonathan D Licht, Márcia R Wink, Keiran S M Smalley
Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment cell & melanoma research 33 (3) (2019)
Dan A Erkes, Conroy O Field, Claudia Capparelli, Manoela Tiago, Timothy J Purwin, Inna Chervoneva, Adam C Berger, Edward J Hartsough, Jessie Villanueva, Andrew E Aplin
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner. Pigment cell & melanoma research 32 (5) (2019)
Valérie Petit, Jeremy Raymond, Christophe Alberti, Marie Pouteaux, Stuart J Gallagher, Mai Q Nguyen, Andrew E Aplin, Véronique Delmas, Lionel Larue
C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo. Pigment cell & melanoma research 32 (6) (2019)

Andrew E Aplin.css-eqlu8i{font-size:small;padding-left:4px;}